Biogen Idec Inc (BIIB) 290.54 $BIIB
AbbVie Candidate in Pivotal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:32AM CDT
AbbVie's experimental cancer drug veliparib has been moved into a pivotal study.
Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights ...
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 2.10% Gain
Comtex SmarTrend(R) - Wed Apr 16, 4:04PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $284.07 to a high of $294.00. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $292.80 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Idec Rises 2.10% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 16, 4:04PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $284.07 to a high of $294.00. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $292.80 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
3 Biotech Opportunities Following This Selloff
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 8:30AM CDT
Since the end of February, the iShares NASDAQ Biotechnology Index has been hammered by about 19%. The most speculative companies have been the hardest hit, but several gems (with marketed products driving growth) have also taken a beating. ...
'Fast Money' Recap: Impressed by Yahoo!
at The Street - Wed Apr 16, 4:00AM CDT
The trading panel discussed Yahoo!'s earnings and Alibaba's IPO.
RBCC Bioprinting Partner Expands Brand Awareness Campaign
Business Wire - Wed Apr 16, 3:28AM CDT
Rainbow Coral Corp.'s (OTCBB: RBCC) 3D bioprinting partner, Nano3D Biosciences (n3D), has presented their groundbreaking technology at two high-profile events in recent weeks as part of a campaign to build brand awareness around the revolutionary BiO Assay system.
Health Care Stocks: Check Out This Low-Cost Market Beater
Selena Maranjian, The Motley Fool - Motley Fool - Tue Apr 15, 4:15PM CDT
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some health care stocks to your portfolio but don't have the time or expertise to hand-pick a few, the iShares US Healthcare ETF ...
Biotech Bubble Bust: 2 Ways to Win
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Tue Apr 15, 1:08PM CDT
Are biotech stocks in a bubble? Is that bubble collapsing? These are the two questions at the forefront of investors' minds. Given the tremendous run of biotech stocks, the iShares NASDAQ Biotechnology Index is up 80% over the last 2 years, it's...
Surveyed European Neurologists Expect to Prescribe Biogen Idec's Tecfidera to 16 Percent of their Diagnosed Relapsing-Remitting Multiple Sclerosis Patients in the Next 12 Months
PR Newswire - Tue Apr 15, 12:00PM CDT
Decision Resources Group finds that surveyed neurologists in France, Germany, Italy, Spain, and the United Kingdom (EU5) project that 16 percent of their diagnosed relapsing-remitting multiple sclerosis (MS) patients on average will receive Biogen Idec's Tecfidera within the next year, which is slightly higher than the 13 percent share they ascribe for Sanofi/Genzyme's Aubagio. In a survey fielded until February 2014, respondents indicated that future prescribing of both first-line-eligible oral disease-modifying therapies (DMTs) will be most encouraged through greater familiarity, improved access/reimbursement, or additional data supporting use.
Will Abbott Labs (ABT) Disappoint This Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 10:30AM CDT
Abbott Laboratories is scheduled to report first quarter 2014 results before the opening bell on Apr 16, 2014.
Stocks: Thin Gains; Yellen Coaxes Banks To Fortify
at Investor's Business Daily - Tue Apr 15, 9:40AM CDT
Stocks rolled up early gains in weak trade, as soft economic news did little to coax investors off the sidelines. The S&P 500 and the Dow Jones industrial average scrambled ahead 0.4%. The Nasdaq fought to hold a fractional gain. Volume opened on...
Are Biotechs Bad Medicine for the S&P 500?
George Budwell, The Motley Fool - Motley Fool - Tue Apr 15, 8:30AM CDT
The S&P 500 is a closely watched indicator of the U.S. economy that has started to falter over the past few weeks. Specifically, the S&P 500 is now down over 2% in the last month, although it's still up about 15% over the last year....
Gilead Bucks Biotech Trend Thanks to Sovaldi News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 10:30AM CDT
Gilead gained on news related to Sovaldi.
Biogen Idec Shares Down 10.1% Since SmarTrend's Sell Call (BIIB)
Comtex SmarTrend(R) - Mon Apr 14, 9:27AM CDT
SmarTrend identified a Downtrend for Biogen Idec (NASDAQ:BIIB) on March 24th, 2014 at $311.16. In approximately 3 weeks, Biogen Idec has returned 10.10% as of today's recent price of $279.74.
Stock Market News for April 14, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 9:06AM CDT
Another day of selling pressure in bio-tech and technology stocks dragged the benchmarks down on Friday
Will Johnson & Johnson (JNJ) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 9:00AM CDT
Johnson & Johnson has an Earnings ESP of 0.00% with a Zacks Rank #2 (Buy).
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting
Business Wire - Mon Apr 14, 6:30AM CDT
--- New TECFIDERA(R) (dimethyl fumarate) Data Underscore Efficacy, Consistent with Growing Global Experience with Greater than 65,000 Patients Treated Worldwide(1) -
AbbVie Candidate in Pivotal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:32AM CDT
AbbVie's experimental cancer drug veliparib has been moved into a pivotal study.
Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc.
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 17, 8:30AM CDT
Biotech stocks have taken a punishing nose-dive over the past month as investors step aside following significant gains. However, the current share slide is likely more a result of emotion than any long-term changes at drug developer heavyweights ...
Biotech Stock Mailbag: NeoStem, Gilead and the Importance of Big-Cap Biotech Earnings
at The Street - Thu Apr 17, 8:18AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 2.10% Gain
Comtex SmarTrend(R) - Wed Apr 16, 4:04PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $284.07 to a high of $294.00. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $292.80 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Idec Rises 2.10% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Apr 16, 4:04PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $284.07 to a high of $294.00. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $292.80 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
3 Biotech Opportunities Following This Selloff
Cory Renauer, The Motley Fool - Motley Fool - Wed Apr 16, 8:30AM CDT
Since the end of February, the iShares NASDAQ Biotechnology Index has been hammered by about 19%. The most speculative companies have been the hardest hit, but several gems (with marketed products driving growth) have also taken a beating. ...
'Fast Money' Recap: Impressed by Yahoo!
at The Street - Wed Apr 16, 4:00AM CDT
The trading panel discussed Yahoo!'s earnings and Alibaba's IPO.
RBCC Bioprinting Partner Expands Brand Awareness Campaign
Business Wire - Wed Apr 16, 3:28AM CDT
Rainbow Coral Corp.'s (OTCBB: RBCC) 3D bioprinting partner, Nano3D Biosciences (n3D), has presented their groundbreaking technology at two high-profile events in recent weeks as part of a campaign to build brand awareness around the revolutionary BiO Assay system.
Health Care Stocks: Check Out This Low-Cost Market Beater
Selena Maranjian, The Motley Fool - Motley Fool - Tue Apr 15, 4:15PM CDT
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some health care stocks to your portfolio but don't have the time or expertise to hand-pick a few, the iShares US Healthcare ETF ...
Biotech Bubble Bust: 2 Ways to Win
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Tue Apr 15, 1:08PM CDT
Are biotech stocks in a bubble? Is that bubble collapsing? These are the two questions at the forefront of investors' minds. Given the tremendous run of biotech stocks, the iShares NASDAQ Biotechnology Index is up 80% over the last 2 years, it's...
Surveyed European Neurologists Expect to Prescribe Biogen Idec's Tecfidera to 16 Percent of their Diagnosed Relapsing-Remitting Multiple Sclerosis Patients in the Next 12 Months
PR Newswire - Tue Apr 15, 12:00PM CDT
Decision Resources Group finds that surveyed neurologists in France, Germany, Italy, Spain, and the United Kingdom (EU5) project that 16 percent of their diagnosed relapsing-remitting multiple sclerosis (MS) patients on average will receive Biogen Idec's Tecfidera within the next year, which is slightly higher than the 13 percent share they ascribe for Sanofi/Genzyme's Aubagio. In a survey fielded until February 2014, respondents indicated that future prescribing of both first-line-eligible oral disease-modifying therapies (DMTs) will be most encouraged through greater familiarity, improved access/reimbursement, or additional data supporting use.
Will Abbott Labs (ABT) Disappoint This Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 10:30AM CDT
Abbott Laboratories is scheduled to report first quarter 2014 results before the opening bell on Apr 16, 2014.
Stocks: Thin Gains; Yellen Coaxes Banks To Fortify
at Investor's Business Daily - Tue Apr 15, 9:40AM CDT
Stocks rolled up early gains in weak trade, as soft economic news did little to coax investors off the sidelines. The S&P 500 and the Dow Jones industrial average scrambled ahead 0.4%. The Nasdaq fought to hold a fractional gain. Volume opened on...
Are Biotechs Bad Medicine for the S&P 500?
George Budwell, The Motley Fool - Motley Fool - Tue Apr 15, 8:30AM CDT
The S&P 500 is a closely watched indicator of the U.S. economy that has started to falter over the past few weeks. Specifically, the S&P 500 is now down over 2% in the last month, although it's still up about 15% over the last year....
Gilead Bucks Biotech Trend Thanks to Sovaldi News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 10:30AM CDT
Gilead gained on news related to Sovaldi.
Biogen Idec Shares Down 10.1% Since SmarTrend's Sell Call (BIIB)
Comtex SmarTrend(R) - Mon Apr 14, 9:27AM CDT
SmarTrend identified a Downtrend for Biogen Idec (NASDAQ:BIIB) on March 24th, 2014 at $311.16. In approximately 3 weeks, Biogen Idec has returned 10.10% as of today's recent price of $279.74.
Stock Market News for April 14, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 9:06AM CDT
Another day of selling pressure in bio-tech and technology stocks dragged the benchmarks down on Friday
Will Johnson & Johnson (JNJ) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 9:00AM CDT
Johnson & Johnson has an Earnings ESP of 0.00% with a Zacks Rank #2 (Buy).
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting
Business Wire - Mon Apr 14, 6:30AM CDT
--- New TECFIDERA(R) (dimethyl fumarate) Data Underscore Efficacy, Consistent with Growing Global Experience with Greater than 65,000 Patients Treated Worldwide(1) -
